KontRASt-02: A phase III trial investigating the efficacy and safety of the KRASG12C inhibitor JDQ443 vs docetaxel in patients with previously treated, locally advanced or metastatic, KRAS G12C-mutated NSCLC.

被引：0
|
作者：
Cappuzzo, Federico
Castro, Gilberto
Kang, Jin-Hyoung
Wu, Yi-Long
Brustugun, Odd Terje
Cheema, Parneet Kaur
Owonikoko, Taofeek K.
Longin, Anne-Sophie
Boran, Aislyn
Duan, Jiawei
Caparica, Rafael
Loong, Herbert H. F.
机构：
[1] AUSL Romagna, Dept Hematol, Ravenna, Italy
[2] Univ Sao Paulo, Sao Paulo, Brazil
[3] Catholic Univ Korea, Dept Internal Med, Seoul, South Korea
[4] Guangdong Lung Canc Inst, Guangzhou, Peoples R China
[5] Vestre Viken HF, Drammen Hosp, Sect Oncol, Drammen, Norway
[6] Univ Toronto, William Osler Hlth Syst, Brampton, ON, Canada
[7] UPMC Hillman Canc Ctr, Pittsburgh, PA USA
[8] Novartis Pharmaceut, Paris, France
[9] Novartis Pharmaceut, E Hanover, NJ USA
[10] Novartis Pharma AG, Basel, Switzerland
[11] Chinese Univ Hong Kong, Hong Kong, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS9144
引用
收藏
页数：1
相关论文
共 27 条
  • [1] KontRASt-02: A Phase III Trial Investigating the Efficacy and Safety of the KRASG12C Inhibitor JDQ443 vs. Docetaxel in Patients with Previously Treated, Locally Advanced or Metastatic, KRAS G12C-Mutated NSCLC
    Cappuzzo, F.
    Castro Junior, G.
    Kang, J. H.
    Wu, Y. L.
    Brustugun, O. T.
    Cheema, P. K.
    Owonikoko, T. K.
    Longin, A. S.
    Duan, J.
    Caparica, R.
    Loong, H. H. F.
    Chan, E.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (01): : E14 - E14
  • [2] KontRASt-01 Update: Safety and Efficacy of JDQ443 in KRAS G12C-Mutated Solid Tumors Including Non-Small Cell Lung Cancer (NSCLC)
    Cassier, P.
    Dooms, C.
    Gazzah, A.
    Felip, E.
    Steeghs, N.
    Rohrberg, K. S.
    De Braud, F.
    Solomon, B.
    Schuler, M.
    Tan, D. S.
    Yamamoto, N.
    Loong, H. H. F.
    Cho, B. C.
    Wolf, J.
    Lin, C. C.
    Negrao, M. V.
    Werner, L.
    Cui, X.
    Farago, A. F.
    DeMiguel, M. J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (01): : E4 - E5
  • [3] KontRASt-01 update: safety and efficacy of JDQ443 in KRAS G12C-mutated solid tumors including non-small cell lung cancer (NSCLC)
    Schuler, M.
    Cassier, P. A.
    Dooms, C.
    Gazzah, A.
    Felip, E.
    Steeghs, N.
    Rohrberg, K. S.
    De Braud, F.
    Solomon, B.
    Tan, D. S.
    Yamamoto, N.
    Loong, H. H.
    Cho, B. C.
    Wolf, J.
    Lin, C. -C
    Negrao, M.
    Werner, L.
    Cui, X.
    Farago, A. F.
    de Miguel, M. J.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 147 - 148
  • [4] KontRASt-01: Preliminary Safety and Efficacy of JDQ443+TNO155 in Patients with Advanced, KRAS G12C-Mutated Solid Tumors
    Negrao, M. V.
    Cassier, P. A.
    Solomon, B.
    Schuler, M.
    Rohrberg, K.
    Cresta, S.
    Dooms, C.
    Tan, D. S. W.
    Loong, H. H-F.
    Amatu, A.
    Assmann, K. Krueger
    Fairchild, L.
    Sansregret, L.
    Fan, L.
    Farago, A. F.
    Cho, B. C.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S117 - S118
  • [5] KontRASt-01 update: Safety and efficacy of JDQ443 in KRAS G12C-mutated solid tumors including non-small cell lung cancer (NSCLC)
    Cassier, Philippe Alexandre
    Dooms, Christophe Alfons
    Gazzah, Anas
    Felip, Enriqueta
    Steeghs, Neeltje
    Rohrberg, Kristoffer Staal
    De Braud, Filippo G.
    Solomon, Benjamin J.
    Schuler, Martin H.
    Tan, Daniel Shao-Weng
    Yamamoto, Noboru
    Loong, Herbert H. F.
    Cho, Byoung Chul
    Wolf, Juergen
    Lin, Chia-Chi
    Negrao, Marcelo Vailati
    Werner, Lillian
    Cui, Xiaoming
    Farago, Anna F.
    de Miguel, Maria J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [6] KontRASt-01: A Phase Ib/II Dose Escalation Study of JDQ443 in Patients with advanced KRAS G12C mutated solid Tumors
    Schuler, M.
    Tan, D. S.
    Shimizu, T.
    Solomon, B.
    Heist, R. S.
    de Miguel, M.
    Gazzah, A.
    Wermke, M.
    Dooms, C.
    Loong, H. H.
    Steeghs, N.
    Felip, E.
    Steuer, C. E.
    Van Cutsem, E.
    Soo, R. A.
    Jaeger, A.
    Kim, J.
    Xu, K.
    Cui, X.
    Burks, H.
    Farago, A. F.
    Cassier, P. A.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 29 - 29
  • [7] Sotorasib (960 mg or 240 mg) once daily in patients with previously treated KRAS G12C-mutated advanced NSCLC
    Hochmair, Maximilian J.
    Vermaelen, Karim
    Mountzios, Giannis
    Carcereny, Enric
    Dooms, Christophe
    Lee, Se-Hoon
    Morocz, Eva
    Kato, Terufumi
    Ciuleanu, Tudor-Eliade
    Dy, Grace K.
    Parente, Barbara
    O'Byrne, Kenneth J.
    Chu, Quincy S.
    De Castro Junior, Gilberto
    Girard, Nicolas
    Snyder, Wendy
    Tran, Qui
    Kormany, William
    Houk, Brett
    Mehta, Bhakti
    Curioni-Fontecedro, Alessandra
    EUROPEAN JOURNAL OF CANCER, 2024, 208
  • [8] KROCUS: A phase II study investigating the efficacy and safety of fulzerasib (GFH925) in combination with cetuximab in patients with previously untreated advanced KRAS G12C mutated NSCLC.
    Gregorc, Vanesa
    Gonzalez-Cao, Maria
    Salvagni, Stefania
    Koumarianou, Anna
    Gil-Bazo, Ignacio
    Maio, Michele
    Viteri, Santiago
    Majem, Margarita
    Gutierrez, Vanesa
    Caro, Reyes Bernabe
    Sanmamed, Miguel F.
    Zhu, Huaqiang
    Shen, Haige
    Wang, Yu
    Rosell, Rafael
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA8511 - LBA8511
  • [9] Patient-reported outcomes from the CodeBreaK 200 phase III trial comparing sotorasib versus docetaxel in KRAS G12C-mutated NSCLC
    Waterhouse, D. M.
    Rothschild, S.
    Dooms, C.
    Mennecier, B.
    Bozorgmehr, F.
    Majem, M.
    van den Heuvel, M.
    Linardou, H.
    Chul-Cho, B.
    Roberts-Thomson, R.
    Okamoto, I.
    Blais, N.
    Schvartsman, G.
    Holmskov, K.
    Chmielewska, I.
    Forster, M.
    Stollenwerk, B.
    Obiozor, C. C.
    Wang, Y.
    Novello, S.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S37 - S38
  • [10] A phase 1b study evaluating the safety and efficacy of sotorasib, a KRASG12C inhibitor, in combination with trametinib, a MEK inhibitor, in KRAS p.G12C-Mutated Solid Tumors
    Ramalingam, Suresh
    Fakih, Marwan
    Strickler, John
    Govindan, Ramaswamy
    Li, Bob T.
    Goldberg, Sarah
    Gandara, David
    Burns, Timothy
    Barve, Minal
    Shu, Catherine
    Frank, Richard
    Sohal, Davendra
    Jafarinasabian, Pegah
    Dai, Tian
    Mather, Omar
    Hong, David
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
123